COTA expands clinicogenomics offering with Genomic Testing Cooperative partnership.
Subscribe on your favorite platform:
[00:13] Introduction — Zoe Li introduces Paul Simms, a Managing Partner at Impatient Health.
[04:19] Pharma industry is not patient-centric — Pharma companies are science-driven, so they are science-centric, Paul explains. These companies are trying to find chemical and biological formulas that work for patients. On the other hand, patient advocacy and patient engagement are much more definable from the industry’s perspective.
[08:20] The patient engagement — Paul says immersion and closeness are the solutions because if you want to understand the problem, you need to experience it. So, if pharma companies want to deliver value, they need to immerse themselves in patients’ lives or simulate certain conditions.
[12:22] The importance of systematization within the industry — The goal is to find formulas that work for patients, so even uncaring personalities working within the pharma industry must be interested in the best solutions. ”You don’t have to care to be patient-centric, which sounds almost paradoxical, but it should be systemized to such a degree that that is the case,” Paul states.
[15:05] Leadership and healthcare — The issue with healthcare and leadership is that everyone talks about past or present actions, and no one wants to talk about the future and innovations.
[18:10] Setting the goal — Innovation and creativity within the industry is of the utmost importance. Even though these actions draw attention, it is not the wrong kind of attention. The public will want to know how far you come because movement differentiates you from others. ”Ambition is not just saying let’s move in the right direction, but let’s say we’re going to go here.”
[20:45] Patients and data — It sounds arrogant to say that patients shouldn’t have all of their data because they don’t know what to do with it. One of the things Paul learned was never to underestimate patients.
[27:17] Safety first — The pharma industry is necessarily conservative. Drug development doesn’t allow irresponsible experiments and compromises.
[29:11] Who’s responsible for innovation in our organizations? — The explosion of science and discoveries, especially within medicine, are ”truly mind-boggling”, Simms says. However, the pandemic came and changed the priorities. Now, there is less money in the system. ”We need to refocus who’s responsible for innovation in our organizations. Is it just the R&D department, or is it all of us outside of R&D?
[33:17] Heroes from the frontline — When the world needed a COVID vaccine, experts united. However, heroes are on the frontline. Unfortunately, they are a minority. The truth is, 90% of the industry has not transformed. That’s not acceptable, Simms concludes.
[35:23] The internet became faster and more ubiquitous — We are still exploring the digital space, Paul notices. Everything we’ve done so far is just the first version. ”We’ve only explored the conversion of what happened offline into an online picture.”